Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.56 |
| ▸ | PRCP | P42785 | 1/20 | 0.51 |
| ▸ | CD44 | P16070 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2259424 | 0.98 | PNMT (0.54) | PNMTPRCPCD44MAOBHTR2C | |
| SCHEMBL11337766 | 0.90 | PNMT (0.46) | PNMTPRCPCD44MAOBHTR2C | |
| SCHEMBL30218840 | 0.86 | CD44 (0.56) | PNMTPRCPCD44MAOBHTR2C | |
| SCHEMBL798791 | 0.86 | CD44 (0.56) | PNMTPRCPCD44MAOBHTR2C | |
| SCHEMBL5964026 | 0.85 | PRCP (0.60) | PNMTPRCPCD44MAOBHTR2C | |
| Hydrochloric Acid SCHEMBL2260124 | 0.84 | CD44 (0.54) | PNMTPRCPCD44MAOBHTR2C | |
| SCHEMBL8675324 | 0.83 | HTR2C (0.41) | PNMTCD44HTR2CHTR2AHTR2B | |
| SCHEMBL12903032 | 0.82 | PNMT (0.56) | PNMTPRCPCD44MAOBHTR2C | |
| Hydrochloric Acid SCHEMBL2657655 | 0.81 | HTR2C (0.40) | PNMTCD44HTR2CHTR2AHTR2B | |
| SCHEMBL11739968 | 0.77 | HTR2A (0.47) | PNMTPRCPHTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855471-A1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2015-04-08 | — | — | EP | claimed |
| WO-2013177024-A1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-28 | — | — | WO | claimed |
| EP-3568390-B1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024005526-A1 | NOVEL COMPOUND AS NADPH OXIDASE 2 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 동국대학교 산학협력단 | 2024-01-04 | — | — | WO | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4245295-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | Alkahest, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230116770-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| US-11452717-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-27 | — | — | US | disclosed |
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-06-03 | — | — | US | disclosed |
| WO-2006079467-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F. HOFMANN-LA ROCHE AG (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20060167023-A1 | Substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1680137-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | Intermune, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| US-4228170-A | INHIBITOR OF PHENYLETHANOLAMINE N-METHYLTRANSFERASE | SMITHKLINE CORPORATION (US) | 1980-10-14 | — | — | US | disclosed |
| US-4062961-A | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES | SMITHKLINE CORPORATION (US) | 1977-12-13 | — | — | US | disclosed |
| US-3988339-A | 7 OR 8-SUBSTITUTED 1,2,3,4-TETRAHYDRO-ISOQUINOLINE | SMITHKLINE CORPORATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167023-A1 | Substituted phenyl methanones | SLC6A7, SLC1A1, SLC26A3 | PNMT 664/4885PRCP 1056/4885CD44 4799/4885 |
| US-11452717-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | PNMT 364/4885PRCP 2104/4885CD44 4598/4885 |
| US-20210161873-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | NAMPT, NAPRT, NNT | PNMT 364/4885PRCP 2104/4885CD44 4598/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | PNMT 364/4885PRCP 2104/4885CD44 4598/4885 |
| US-20230116770-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | NAMPT, NAPRT, NNT | PNMT 364/4885PRCP 2104/4885CD44 4598/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | PNMT 2339/4885PRCP 974/4885CD44 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.